Viyash Scientific Secures Shareholder Approval for New Leadership and ESOP Grant

Viyash Scientific ( (IN:VIYASH) ) just unveiled an update.

Viyash Scientific Limited has announced that shareholders have approved, via remote e-voting through a postal ballot, several key management appointments and compensation matters, including the appointment and remuneration of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term. Investors also cleared special resolutions to grant stock options exceeding 1% of the company’s issued capital to an identified employee in a single year, and to appoint Rajaram Narayanan and Srinivas Vasireddy as whole-time directors, moves that consolidate the leadership team and signal a focus on executive stability and incentive alignment.

The company confirmed that all four special resolutions were passed with the requisite majority as of March 12, 2026, in compliance with Regulation 44 of SEBI’s Listing Obligations and Disclosure Requirements. By securing shareholder backing for these governance and remuneration measures, Viyash Scientific strengthens its management structure, potentially enhancing strategic execution and corporate oversight, with details of the voting outcomes and the scrutinizer’s report made available on its website for investor transparency.

More about Viyash Scientific

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is an India-based listed company with its registered office in Hyderabad and its shares traded on both BSE and the National Stock Exchange of India under the symbol VIYASH. The company operates in the broader scientific and pharmaceutical-related sector, with a shareholder base engaged through remote e-voting and postal ballot mechanisms in line with Indian listing regulations.

Average Trading Volume: 37,982

Technical Sentiment Signal: Buy

Current Market Cap: 85.41B INR

Learn more about VIYASH stock on TipRanks’ Stock Analysis page.